Voyager Therapeutics (VYGR) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $208.9 million.
- Voyager Therapeutics' Cash & Current Investments fell 3950.37% to $208.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.9 million, marking a year-over-year decrease of 3950.37%. This contributed to the annual value of $266.7 million for FY2024, which is 1551.01% up from last year.
- As of Q3 2025, Voyager Therapeutics' Cash & Current Investments stood at $208.9 million, which was down 3950.37% from $215.6 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Cash & Current Investments registered a high of $399.6 million during Q1 2024, and its lowest value of $118.8 million during Q4 2022.
- Over the past 5 years, Voyager Therapeutics' median Cash & Current Investments value was $215.6 million (recorded in 2025), while the average stood at $220.9 million.
- Per our database at Business Quant, Voyager Therapeutics' Cash & Current Investments skyrocketed by 9426.07% in 2023 and then plummeted by 4189.2% in 2025.
- Over the past 5 years, Voyager Therapeutics' Cash & Current Investments (Quarter) stood at $132.5 million in 2021, then dropped by 10.33% to $118.8 million in 2022, then skyrocketed by 94.26% to $230.9 million in 2023, then grew by 15.51% to $266.7 million in 2024, then fell by 21.66% to $208.9 million in 2025.
- Its Cash & Current Investments was $208.9 million in Q3 2025, compared to $215.6 million in Q2 2025 and $236.0 million in Q1 2025.